Compare ClearPoint Neuro Inc (CLPT) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs TotalEnergies SE — how do they compare? ClearPoint Neuro Inc trades at $16.05 (market cap $478.63M), while TotalEnergies SE trades at $81.44 (market cap $180.15B). The key difference: TotalEnergies SE is far larger — about 376.4× ClearPoint Neuro Inc's market cap, and TotalEnergies SE pays a 5.21% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | TTE | |
|---|---|---|
Market Cap | $478.63M | $180.15B |
Sector | Health | Energy |
52-Week High | $29.60 | $93.60 |
52-Week Low | $8.66 | $57.39 |
Enterprise Value | $506.63M | $214.29B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
TotalEnergies (TTE) trades at $81.21, up 3.45% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $2.45, beating expectations, but revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation ratios are attractive with a P/E of 12.05 and EV/EBITDA of 4.93. Recent news highlights strategic moves in LNG and solar divestments to focus on larger renewable projects.
The outlook for TTE is supported by strong cash flow generation and a 'Buy' consensus from 57.6% of analysts, but risks include declining revenue trends, geopolitical exposure, and regulatory pressures. The stock offers value with solid profitability and shareholder returns via dividends, yet investors should weigh execution risks in its energy transition strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
